Naloxone Oral Syringes

The Medical Readiness Contracting Officer- W (MRCO-W) is issuing this Sources Sought Notice on behalf of Brooke Army Medical Center to find potential sources to provide Naloxone oral syringes for patients by the Inpatient Section. THIS IS NOT A SOLICITATION ANNOUNCEMENT – This is a Sources Sought Notice and is issued solely for information and planning purposes – it does not constitute a Request for Quote (RFQ) or a promise to issue an RFQ in the future.

Solicitations are not available at this time and requests for a solicitation will not receive a response. This notice does not constitute a commitment by the United States Government to contract for any supply or service whatsoever. All information submitted in response to this announcement is voluntary; the United States Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the United States Government.

Not responding to this Sources Sought Notice does not preclude participation in any future Request for Quote (RFQ), should one be issued. It is the responsibility of the potential offerors to monitor this site for additional information pertaining to this requirement. The Government will use responses to this notice in formulating its acquisition strategy.

If the Government does not receive sufficient information in response to this notice to verify the potential for competition exists, it is possible that a sole-source contract, supported by a Justification and Approval document, will be issued to support the Government's requirement.

MRCO-W is seeking the following information (please answer paragraphs below with your response): Company name, Unique Entity ID, CAGE code, and point of contact information (including phone number and email address), and socio-economic category(ies) as related to PSC 6505 – Drugs and Biologicals and NAICS 325412 – Pharmaceutical Preparation Manufacturing, such as 8(a), HUBZone, Women-Owned, Service-Disabled Veteran-Owned, Small, or Other-than-Small.

Capability Statement (limited to ten pages), describing how your company meets the below objectives additional proof (such as product literature and locations where a system is currently installed) where appropriate.

Naloxone and compounded pharmaceuticals must meet the below salient characteristics: Naloxone 1mg/mL 2mL Oral Syringe Will contain a solution of Naloxone 1mg/ml packaged in 2mL oral syringe Will be packaged in an oral syringe with a tamper evident cap and without a luer lock tip Will be labeled for oral use only Must have a Beyond Use Date of no less than 30 days Ketamine 10mg/mL in Normal Saline 5mL in 10mL OR Syringe Will contain ketamine 10mg/mL mixed with Normal Saline 5mL packaged in a 10mL OR syringe Will have a label affixed to each syringe specifying the contents Must have a Beyond Use Date of no less than 30 days Ketamine 10mg/mL in Normal Saline 10mL in 10mL OR Syringe Will contain ketamine 10mg/mL mixed with Normal Saline 10mL packaged in a 10mL OR syringe Will have a label affixed to each syringe specifying the contents Must have a Beyond Use Date of no less than 30 days Norepinephrine 4mg in D5W 250mL bag Will contain norepinephrine 4mg added to 250mL bag of dextrose 5% in water Will have a label affixed to each bag specifying the contents Must have a Beyond Use Date of no less than 30 days Norepinephrine 8mg in D5W 250mL bag Will contain norepinephrine 8mg added to 250mL bag of dextrose 5% in water Will have a label affixed to each bag specifying the contents Must have a Beyond Use Date of no less than 30 days Period of Performance is October 2025 through September 2026 with four (4) Option Years.

The response due date for this Sources Sought Notice is 10:00 AM CST, 24 July 2025. All questions and comments regarding this announcement shall be submitted via e-mail to the below POCs: dulce.i.bares.civ@health.mil